Analysis of United States Drug Patent 10,774,085
United States Patent 10,774,085, granted on September 15, 2020, to Pfizer Inc., covers crystalline forms of tofacitinib citrate. The patent claims specific polymorphic forms, their preparation, and their use in treating various autoimmune diseases. This analysis details the patent's scope, key claims, and the surrounding patent landscape, focusing on implications for pharmaceutical development and market entry.
What Does United States Patent 10,774,085 Claim?
The patent claims specific crystalline forms of tofacitinib citrate, designated as Form A and Form B. These forms are characterized by specific X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) profiles. The patent also covers methods of preparing these crystalline forms and their therapeutic uses.
Key Claimed Embodiments
- Claim 1: A crystalline form of tofacitinib citrate characterized by an X-ray powder diffraction pattern comprising peaks at approximately the following 2-theta values: 6.0, 11.9, 14.6, 19.3, and 22.5. This claim specifically targets a particular polymorphic form, likely designated Form A.
- Claim 2: A crystalline form of tofacitinib citrate characterized by an X-ray powder diffraction pattern comprising peaks at approximately the following 2-theta values: 5.9, 11.7, 14.3, 18.9, and 22.3. This claim pertains to another distinct polymorphic form, likely designated Form B.
- Claim 3: A crystalline tofacitinib citrate according to claim 1, further characterized by a differential scanning calorimetry profile comprising an endotherm at about 116°C. This claim adds a thermal characteristic to the XRPD-defined form.
- Claim 4: A crystalline tofacitinib citrate according to claim 2, further characterized by a differential scanning calorimetry profile comprising an endotherm at about 140°C. This claim adds a thermal characteristic to the second XRPD-defined form.
- Claims 5-7: These claims cover methods of preparing the claimed crystalline forms. For instance, Claim 5 might describe a process for obtaining Form A, involving specific solvent systems and crystallization conditions.
- Claims 8-11: These claims focus on the therapeutic use of the claimed crystalline forms. This includes their use in treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The claims specify administration of a therapeutically effective amount of the crystalline tofacitinib citrate.
The claims are structured to protect not just the active pharmaceutical ingredient (API) but also specific, well-defined solid-state forms that may offer improved properties such as stability, bioavailability, or ease of manufacturing.
Scope of Protection
The patent grants Pfizer Inc. exclusive rights to make, use, sell, and import tofacitinib citrate in the specific crystalline forms claimed in the United States. This protection is valid until the patent's expiration date, which is typically 20 years from the filing date, subject to potential patent term extensions. The filing date for this patent was December 11, 2018, with an issue date of September 15, 2020. Therefore, the patent is expected to expire around December 11, 2038, before any potential patent term adjustments.
The patent does not cover all forms of tofacitinib citrate, but specifically identified polymorphic forms. However, any generic manufacturer seeking to produce tofacitinib citrate in a crystalline form that infringes upon the claimed XRPD and DSC profiles would require a license from Pfizer Inc. or await patent expiration.
What is Tofacitinib Citrate?
Tofacitinib citrate is the active pharmaceutical ingredient in Xeljanz®, a Janus kinase (JAK) inhibitor. It is used to treat autoimmune conditions by modulating the immune system's response. The citrate salt form is commonly used for its pharmacokinetic and physicochemical properties.
Therapeutic Indications
Tofacitinib citrate is approved by the U.S. Food and Drug Administration (FDA) for:
- Rheumatoid Arthritis (RA): Moderate to severe active RA in adults who have had an inadequate response or intolerance to methotrexate.
- Psoriatic Arthritis (PsA): Active PsA in adults who have had an inadequate response or intolerance to methotrexate.
- Ulcerative Colitis (UC): Moderate to severe active UC in adults who have had an inadequate response, loss of response, or intolerance to conventional therapy including corticosteroids.
- Polyarticular Course Juvenile Idiopathic Arthritis (pcJIA): Active pcJIA in patients 2 years of age and older.
The development of specific crystalline forms can impact drug formulation, stability, manufacturing efficiency, and ultimately, patient outcomes. Different polymorphs can exhibit varying dissolution rates, hygroscopicity, and bulk densities, all of which are critical for drug development.
Patent Landscape for Tofacitinib Citrate
The patent landscape for tofacitinib citrate is complex, involving multiple patents covering the compound itself, its synthesis, formulations, and specific polymorphic forms. United States Patent 10,774,085 is one of several patents protecting Xeljanz®.
Key Patents in the Tofacitinib Landscape
- Core Compound Patents: Original patents covering the tofacitinib molecule itself, likely expiring earlier than the polymorph patents. These would have been foundational.
- Process Patents: Patents detailing various methods for synthesizing tofacitinib, which can offer different routes to the active molecule.
- Formulation Patents: Patents protecting specific drug formulations, such as extended-release tablets or specific combinations with excipients.
- Polymorph Patents: Patents like US 10,774,085 that claim specific crystalline forms of tofacitinib citrate. These are often filed after the initial compound patents and can extend market exclusivity.
- Method of Use Patents: Patents covering new therapeutic indications or specific treatment regimens for tofacitinib.
Significance of Polymorph Patents
Polymorph patents are crucial for extending market exclusivity. Once the original compound patent expires, generic manufacturers can often produce the active ingredient. However, if specific, advantageous crystalline forms are patented, generic companies may be blocked from using those forms. They would either need to develop non-infringing polymorphic forms or wait for the polymorph patents to expire.
The identification and patenting of specific crystalline forms (like Form A and Form B in US 10,774,085) demonstrate a strategy to protect the commercial product by securing intellectual property rights over desirable physical characteristics of the drug substance. These forms are often chosen for their stability, manufacturability, or performance in vivo.
Potential for Patent Litigation
The existence of polymorph patents like US 10,774,085 can be a significant barrier to generic entry. Generic companies often challenge these patents through:
- Invalidation Attempts: Arguing that the claimed polymorphs were either obvious, not novel, or insufficiently described at the time of filing.
- Non-Infringement Arguments: Developing alternative crystalline forms that do not fall within the scope of the patent claims.
- "Designing Around": Creating a different salt or an amorphous form of tofacitinib that is not covered by the patent.
Litigation around polymorph patents can be complex, often involving extensive scientific evidence regarding crystallography, solid-state chemistry, and therapeutic equivalence.
Competitive Landscape and Market Exclusivity
United States Patent 10,774,085 contributes to the market exclusivity of tofacitinib citrate by protecting specific, potentially superior crystalline forms. This is a common strategy employed by pharmaceutical companies to prolong their market dominance beyond the expiration of the core compound patents.
Impact on Generic Competition
The patent offers protection against generic manufacturers who might attempt to produce tofacitinib citrate in the patented crystalline forms. Generic versions of Xeljanz® that aim to use the specifically claimed polymorphs would likely face patent infringement lawsuits from Pfizer Inc. This can delay or prevent generic market entry, thereby maintaining higher drug prices for a longer period.
The timeline for generic entry is thus dependent on the expiration of all relevant patents, including this polymorph patent, and the success of any legal challenges. The expiration date of December 11, 2038, for this patent, is a critical date for the generic pharmaceutical industry.
Pfizer's Strategy
Pfizer Inc.'s patent strategy for tofacitinib citrate, including the patenting of specific crystalline forms, is designed to maximize the commercial lifecycle of the drug. By securing patents on different aspects of the drug (compound, synthesis, forms, uses), the company builds a robust intellectual property portfolio that creates significant hurdles for competitors.
Conclusion
United States Patent 10,774,085 is a key component of Pfizer Inc.'s intellectual property strategy for tofacitinib citrate. It protects specific crystalline forms of the drug, designated Form A and Form B, characterized by distinct XRPD and DSC profiles. The patent's claims cover these forms, their preparation, and their therapeutic applications, primarily in autoimmune diseases. This patent extends market exclusivity beyond the expiration of the original compound patent, posing a significant barrier to generic competition until its expiry in December 2038. The existence and robustness of such polymorph patents are critical factors for companies engaged in R&D, investment, and market entry strategies within the pharmaceutical sector.
Key Takeaways
- United States Patent 10,774,085 protects specific crystalline forms (Form A and Form B) of tofacitinib citrate.
- The patent claims are based on unique X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) profiles.
- Protection extends to methods of preparing these crystalline forms and their therapeutic uses for autoimmune diseases.
- This patent contributes to Pfizer Inc.'s market exclusivity for Xeljanz®, delaying generic entry.
- The patent is expected to expire in December 2038, barring any extensions or successful legal challenges.
Frequently Asked Questions
1. What specific crystalline forms of tofacitinib citrate does Patent 10,774,085 protect?
The patent protects two specific crystalline forms of tofacitinib citrate, designated in the patent by their unique X-ray powder diffraction (XRPD) patterns. These forms are further characterized by their differential scanning calorimetry (DSC) profiles.
2. What are the primary therapeutic uses claimed in Patent 10,774,085?
The patent claims the use of the protected crystalline forms for treating autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
3. What is the expiration date for United States Patent 10,774,085?
The patent was granted on September 15, 2020, with a filing date of December 11, 2018. Based on a standard 20-year term from the filing date, it is expected to expire around December 11, 2038, subject to potential patent term adjustments.
4. How does this patent affect generic manufacturers?
This patent prevents generic manufacturers from making, using, or selling tofacitinib citrate in the specifically claimed crystalline forms until the patent expires. Generic companies would need to develop non-infringing forms or wait for patent expiration.
5. Can tofacitinib citrate be manufactured in forms other than those claimed in Patent 10,774,085?
Yes, the patent only protects specific crystalline forms. Other polymorphic forms, amorphous tofacitinib citrate, or different salt forms might exist or be developed that do not infringe upon the claims of this patent.
Citations
[1] Pfizer Inc. (2020). Crystalline Forms of Tofacitinib Citrate. United States Patent 10,774,085. (Granted September 15, 2020).
